Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. Hudis C, et al. Among authors: fornier m. J Clin Oncol. 1999 Apr;17(4):1118. doi: 10.1200/JCO.1999.17.4.1118. J Clin Oncol. 1999. PMID: 10561169 Clinical Trial.
Update on the management of advanced breast cancer.
Fornier M, Munster P, Seidman AD. Fornier M, et al. Oncology (Williston Park). 1999 May;13(5):647-58; discussion 660, 663-4. Oncology (Williston Park). 1999. PMID: 10356685 Free article. Review.
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Seidman AD, et al. Among authors: fornier mn. J Clin Oncol. 2001 May 15;19(10):2587-95. doi: 10.1200/JCO.2001.19.10.2587. J Clin Oncol. 2001. PMID: 11352950 Clinical Trial.
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2001 Dec;7(12):3934-41. Clin Cancer Res. 2001. PMID: 11751485 Clinical Trial.
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: fornier m. Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634. Clin Cancer Res. 2004. PMID: 15355903 Clinical Trial.
103 results